V. Goranova-Marinova

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations.

S. Goranov, P. Pavlov, V. Goranova-Marinova, 2007, Haematologica.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

The ageing patient with haemophilia

E. Berntorp, M. Canaro, V. Goranova-Marinova, 2015, European journal of haematology.

Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.

Z. Grudeva-Popova, V. Goranova-Marinova, A. Linev, 2021, Folia medica.

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Palliative radiotherapy in patients with multiple myeloma.

S. Goranov, M. Yaneva, V. Goranova-Marinova, 2006, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.

P. Georgiev, V. Goranova-Marinova, Katya G Sapunarova, 2020, Folia medica.